RP-HPLC raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-09-07 and is reviewed periodically as new material appears.
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off white powder | Typical lyophilized form |
| Water solubility | Soluble | May need a small organic co-solvent |
| Purity assessment | Chromatographic peak area | Most certificates report a percentage figure |
| Storage temperature | Minus 20 C or lower | Dry, dark, sealed container |
| Identity check | Electrospray mass spectrometry | Compared against theoretical mass |
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Glutathione peroxidase 6 (GPx-6) is an enzyme that in humans is encoded by the GPX6 gene. This gene product belongs to the glutathione peroxidase family, which functions in the detoxification of hydrogen peroxide. It contains a selenocysteine (Sec) residue at its active site. The selenocysteine is encoded by the UGA codon, which normally signals translation termination. The 3' UTR of Sec-containing genes have a common stem-loop structure, the sec insertion sequence (SECIS), which is necessary for the recognition of UGA as a Sec codon rather than as a stop signal. Expression of this gene is restricted to embryos and adult olfactory epithelium.
ATC code D11 Other dermatological preparations is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products. Subgroup D11 is part of the anatomical group D Dermatologicals. Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QD11. ATCvet codes without corresponding human ATC codes are cited with the leading Q in the following list.National versions of the ATC classification may include additional codes not present in this list, which follows the WHO version.
=== Receiver details === In addition to triggering the broadcast signal, the output of the transmitter trigger signal was also sent to the receiver hut. Here it fed the input to a time base generator that drove the X-axis deflection plates of the CRT display. This caused the electron beam in the tube to start moving left-to-right at the instant that the transmission was completed. Due to the slow decay of the pulse, some of the transmitted signal was received on the display. This signal was so powerful it overwhelmed any reflected signal from targets, which meant that objects closer than about 5 miles (8.0 km) could not be seen on the display. To reduce this period even to this point required the receiver to be hand-tuned, selecting the decoupling capacitors and impedance of the power supplies. The receiver system, built by A.C. Cossor to a TRE design, was a multiple-stage superheterodyne. The signal from the selected antennas on the receiver towers was fed through the radiogoniometer and then into a three-stage amplifier, with each stage housed in a metal screen box to avoid interference between the stages. Each stage used a Class B amplifier arrangement of EF8s, special low noise, "aligned-grid" pentodes. The output of the initial amplifier was then sent to the intermediate frequency mixer, which extracted a user-selectable amount of the signal, 500, 200 or 50 kHz as selected by a switch on the console. The first setting allowed most of the signal through, and was used under most circumstances.
Sources: en.wikipedia.org
The process of metalorganic vapour-phase epitaxy (MOCVD) entails pyrolysis of volatile organometallic compounds to give semiconductors, hard coatings, and other applicable materials. The reactions entail thermal degradation of precursors, with deposition of the inorganic component and release of the hydrocarbons as gaseous waste. Since it is an atom-by-atom deposition, these atoms organize themselves into crystals to form the bulk semiconductor. Raw polycrystalline silicon is produced by the chemical vapor deposition of silane gases:
== Further reading == Burger, R., U.S. patent 872,795, "Double walled vessel with a space for a vacuum between the walls," December 3, 1907. Sella, Andrea (August 2008). "Dewar's Flask". Chemistry World: 75. Retrieved 2008-08-30.
== Operation Atlantic Resolve == On 29 March 2017, the Department of Defense reported that Green Berets from 1st Battalion 10th SFG were deployed to Europe to take part in exercise Allied Spirit VI-a multinational training exercise involving military personnel from Canada, Czech Republic, Estonia, Finland, France, Hungary, Germany, Italy, Macedonia, Kosovo, Latvia, the Netherlands, Slovenia, UK and US at the JMRC in Germany, the exercise involved special operations and conventional forces with the aim to increase their effectiveness and/particularly to increase the effectiveness of special operations forces in working together while bolstering the capabilities of partner nations within US European Command's area of responsibility. The Green Berets provided their advise and assist training/skills, whilst working with Estonian Special Operations Task Group troops and Macedonian special operations troops. US Army Major Robert Temple, the special operations force cell planner at the JMRC said that “The primary purpose of this exercise is providing a venue for the 1st Latvian Brigade to train in a Joint Task Force environment and increase their interoperability with both U.S. units as well as other multinational forces.” The exercise is being conducted as part of Operation Atlantic Resolve.
===== Funding freezes ===== From the outset of 2025, NIH funding operations have faced interruptions on an unprecedented scale under the direction of the current executive branch of the U.S. government; disruptions as of March 2025 include the following: • impeding grants for dementia and ALS research; • hindering procurement of necessary resources, such as those for transporting patient blood samples; • preventing a research scientist from consulting with physicians treating children with a devastating rare condition; • interrupting the supply of mice for genetic studies, with years of research being imperiled as a result; • cutting research grants for training doctoral and postdoctoral students. This has led to protests such as the Bethesda Declaration, an open letter from former and current NIH staffers.
Sources: en.wikipedia.org
The mass difference from the linker is large enough for routine detection by mass spectrometry. The unconjugated form gives a single sharp signal at its expected weight. Material that has already reacted with albumin shows a much higher mass and a broadened chromatographic peak.
Yes. Degradation proceeds faster once the powder is dissolved, especially at room temperature or after multiple freeze and thaw cycles. Working solutions are often aliquoted to avoid repeated handling. Lyophilized powder held cold and dry retains its properties far longer.
Truncated sequences, oxidized residues and aggregated forms can all elute near the main peak. Reversed phase chromatography resolves many of these species, so the number of peaks is a useful indicator of synthesis quality. A single peak does not by itself prove correct sequence, which is why mass confirmation is paired with it.
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.